Dell to buy EMC in $67B deal

Dell, the world's third-largest maker of personal computers, has announced plans to buy data storage company EMC for $67 billion in cash and stock--the largest technology deal on record.

Dell will make the purchase with MSD Partners and Silver Lake.

"The combination of Dell and EMC creates an enterprise solutions powerhouse bringing our customers industry leading innovation across their entire technology environment," according to a Dell release about the deal. "Our new company will be exceptionally well-positioned for growth in the most strategic areas of next generation IT including digital transformation, software-defineddata center, converged infrastructure, hybrid cloud, mobile and security."

EMC owns the software-development company Pivotal and enterprise-security firm RSA, as well as 80 percent of the virtualization company VMware. Due to slowing revenue and a declining stock price, some investors had called for a breakup of its businesses. The hedge fund Elliott Management, which owns a 2 percent stake in EMC, has publicly pressured the company to spin off VMware. Under the deal, VMware will remain a publicly-traded company.

The Wall Street Journal reported that EMC had started a strategic review of its business last year. In 2014, the company held talks with both Dell and Hewlett-Packard. The discussions with HP ended before the Palo Alto, Calif., company announced it was splitting its printer and PC businesses.

Market analysts have repeatedly downgraded EMC's stock over the last year, but EMC shares were at $33.15 representing a 19 percent premium over the previous trading day's closing price.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.